Timeline | Total Bilirubin, mg/dL (Reference, 0.2-1.2) | ALT, IU/L (Reference, 17-63) | AST, IU/L (Reference, 15-41) | ALP, IU/L (Reference, 32-91) | Platelet Count, × 109/L (Reference, 150-450) | INR (Reference, <1.0) | Albumin, gm/dL (Reference, 3.5-4.8) |
---|---|---|---|---|---|---|---|
Prior to RAD-140 use, –14 months | 1.0 | 48 | 26 | 82 | 152 | – | 4.6 |
Started RAD-140 | – | – | – | – | – | – | |
Routine PCP office visit, +5 weeks | 1.2 | 313 | 182 | 103 | 180 | 0.8 | 4.4 |
Emergency department encounter, +7 weeks | 10.8 | 171 | 71 | 151 | 263 | 0.85 | 4.1 |
Hepatology office visit, +8 weeks | 32.3 | 125 | 82 | 181 | 305 | 0.96 | 3.9 |
Hepatology office visit, +10 weeks | 24.8 | 212 | 120 | 251 | 310 | 1.47 | 3.0 |
Hospital day 1, +10 weeks, 2 days | 28.7 | 155 | 94 | 232 | 341 | 1.36 | 2.9 |
Hospital day 2 | 26.1 | 134 | 76 | 203 | 312 | 1.46 | 2.5 |
Hospital day 3 | 27.3 | 115 | 62 | 199 | 260 | 1.61 | 2.6 |
Hospital day 4 | 24.3 | 117 | 79 | 194 | 268 | 1.69 | 2.5 |
Postdischarge hepatology office visit, +11 weeks | 38.5 | 143 | 104 | 189 | 299 | 0.84 | 2.9 |
Postdischarge hepatology office visit, +14 weeks | 24.6 | 120 | 118 | 187 | 261 | 0.89 | 2.9 |
Postdischarge hepatology office visit, +18 weeks | 4.9 | 118 | 79 | 118 | 170 | 0.91 | 4.0 |
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; INR, international normalized ratio; PCP, primary care provider.